Healthcare diagnostics company QuidelOrtho (NASDAQ: QDEL) missed Wall Street’s revenue expectations in Q3 2026, with sales falling 11.6% year on year to $618.9 million. The company’s full-year revenue guidance of $2.53 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.31 per share was 73.8% above analysts’ consensus estimates.

Is now the time to buy QDEL? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

QuidelOrtho’s third quarter was marked by persistent headwinds in key markets, driving a negative reaction from investors. Management highlighted that China’s finalized nationwide in vitro diagnostics (IVD) pricing guidelines and weaker demand for respiratory tests in the Point of Care segment were the primary factors behind the company’s year-on-year revenue decline. CEO Brian Blaser acknowledged these challenges, noting that “China revenue declined 45% year-over-year as distributors and customers continued to reduce purchasing and inventory levels related to the nationwide IVD pricing guidelines.” Despite growth in Labs and immunohematology outside China, these gains were not enough to offset the broader pressures.

Looking ahead, QuidelOrtho’s revised guidance reflects continued caution as the company faces uncertainty around China’s provincial pricing implementation and subdued respiratory test demand. Management emphasized a new cost transformation and enterprise restructuring program aimed at improving profitability and cash flow, while maintaining investments in selected growth platforms. CFO Micah Young stated, “The actions we’re taking are designed to align resources with the distinct needs of our customers and markets, strengthen financial discipline, and improve the rigor of our investment decisions.” The company remains focused on supporting its installed base and adapting its commercial model to evolving market dynamics.

Key insights from management’s remarks

Management attributed the quarter’s performance to ongoing weakness in China and Point of Care respiratory testing, while launching a major cost restructuring initiative to address profitability and cash flow.

• China IVD pricing impact: The nationwide implementation of new IVD pricing guidelines in China led to significant revenue headwinds, with management citing accelerated destocking and heightened pricing pressure as ongoing challenges. These regulatory changes resulted in a 45% year-over-year decline in China revenue, with further pressures expected as provinces roll out the new guidelines.
• Point of Care softness: The Point of Care Diagnostics segment, especially respiratory testing, continued to underperform due to lower illness incidence and reduced testing volumes. CEO Brian Blaser attributed a 27% decline in Point of Care revenue to “a softer respiratory testing environment,” impacting both top-line growth and product mix.
• Core Diagnostics stability: Outside China, the Labs and immunohematology businesses demonstrated resilience, growing at low to mid-single-digit rates. Management highlighted broad-based demand in regions such as Latin America, Japan, and Asia Pacific, underscoring the durability of customer relationships and recurring revenue streams in these segments.
• Restructuring and cost transformation: The company announced a new enterprise restructuring program, transitioning to two focused business units—Core Diagnostics and Point of Care Diagnostics. This model aims to deliver over $80 million in annual savings by 2027 through staffing reductions and indirect spend discipline, with the goal of mitigating China-related headwinds and structurally improving profitability.
• Selective investment in innovation: Despite cost-cutting initiatives, QuidelOrtho is maintaining targeted investments in growth platforms, such as the VITROS 450 analyzer and the NULEXA molecular platform. Management believes these launches will strengthen the company’s competitive position and support long-term growth, particularly by expanding into international and near-patient testing markets.

Drivers of future performance

QuidelOrtho’s outlook is shaped by ongoing regulatory challenges in China and efforts to optimize costs while maintaining targeted investments in growth areas.

• China regulatory headwinds: Management expects continued revenue and margin pressure from China due to the phased implementation of IVD pricing guidelines, ongoing customer destocking, and increased competition. The company projects China’s revenue contribution to decline further in 2027, with uncertainty around provincial timelines and pricing changes.
• Cost transformation execution: The new restructuring initiative is expected to generate more than $80 million in annual savings by 2027, primarily from staffing reductions and spending controls. Management emphasized that these actions are intended to offset China-related headwinds and support structural improvements in profitability and free cash flow.
• Product innovation and platform launches: QuidelOrtho is prioritizing investment in the VITROS 450 and NULEXA platforms, aiming to drive adoption across international and Point of Care markets. Management views these launches as central to building a more diverse and resilient revenue base, despite near-term market volatility.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will monitor (1) the pace and effectiveness of QuidelOrtho’s cost transformation and restructuring program, (2) developments in China’s provincial IVD pricing implementation and the resulting impact on revenue, and (3) early adoption rates and customer feedback for new platforms like VITROS 450 and NULEXA. Progress in cash flow improvement and leverage reduction will also be important indicators of management’s execution.

QuidelOrtho currently trades at $13.02, down from $14.09 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Our favorite stocks right now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.